Canary HRD™

HRD Gene Panel

The Canary HRD™ Gene Panel test

Cancer Types

Solid tumors
Turnaround Time

14 days from the time the sample is received
Sample Types

FFPE (solid tumors)

Overview Test Features Compare with others FAQ

Test Features

Comprehensive Analysis

41 HRR genes.

Compare with other companies

Comprehensive comparison of Canary diagnostic solutions with other companies' offerings

Note: Green Color highlighted text indicated test results where Canary has a differentiated advantage.
Test Results	Canary Acuity™	Canary Pulse™	Top U.S. and Indian Competitors
Number of Genes Analyzed via NGS	1091 (+637 Variants)	468 (+37 Variants)	300-500
Therapeutic SNVs and InDels	✓	✓	✓
Amplifications and Deletions	✓	✓	✓
Fusions Genes	✓	✓	✓
Tumor Mutational Burden (TMB)	✓	✓	✓
Microsatellite Instability (MSI)	✓	✓	✓
Homologous Recombination Deficiency (HRD)	✓	✓	✓
Loss of Heterozygosity (LOH)	✓	✓	✓
Comprehensive Proprietary Database of FDA Approved/Clinical Trial Drugs for Corresponding Biomarkers	✓	✓	✓
Depiction of Cancer-Relevant Pathways	✓	✓	✗
Germline Variants Affecting Drug Metabolism	✓	✓	✗
Complete ACMG Oncology Germline Mutational Analysis	✓	✓	✗
In Development
TCR Clonality	✓	✗	✗
HLA Typing	✓	✓	✗

Compare with Canary Tests

Comprehensive comparison of Canary diagnostic solutions


Test Results	Canary Acuity™	Canary Pulse™	Canary Focus™
Number of Genes Analyzed via NGS	1091 (+637 Variants)	468 (+37 Variants)	115+
Therapeutic SNVs and InDels	✓	✓	✓
Amplifications and Deletions	✓	✓	✓
Fusions Genes	✓	✓	✓
Tumor Mutational Burden (TMB)	✓	✓	✗
Microsatellite Instability (MSI)	✓	✓	✓
Homologous Recombination Deficiency (HRD)	✓	✓	✗
Loss of Heterozygosity (LOH)	✓	✓	✓
Comprehensive Proprietary Database of FDA Approved/Clinical Trial Drugs for Corresponding Biomarkers	✓	✓	✓
Depiction of Cancer-Relevant Pathways	✓	✓	✗
Germline Variants Affecting Drug Metabolism	✓	✓	✗
Complete ACMG Oncology Germline Mutational Analysis	✓	✓	✗

Canary HRD™ Frequently Asked Questions